17-10-4　ⓔ文献

  1. Sokal JE, Cox EB, et al: Prognostic discrimination in “good–risk” chronic granulocytic leukemia. Blood, 1984; 63: 789–799.

  2. Hasford J, Pfirrmann M, et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 1998; 90: 850–858.

  3. Druker BJ, Guilhot F, et al: Five–year follow–up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006; 355: 2408–2417.

  4. Hughes TP, Hochhaus A, et al: Long–term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010; 116: 3758–3765.

  5. Hochhaus A, Saglio G, et al. Long–term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5–year update of the randomized ENESTnd trial. Leukemia, 2016; 30: 1044–1054.

  6. Cortes JE, Saglio G, et al: Final 5–year study results of DASISION: the dasatinib versus nilotinib study in treatment–naïve chronic myeloid leukemia patients trial. J Clin Oncol, 2016; 34: 2333–2340.

  7. Kizaki M, Takahashi N, et al: Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic–phase chronic myeloid leukemia over 5–year period: results from the Japanese registry obtained by the new TARGET system. Int J Hematol, 2019; 109: 426–439.

  8. Baccarani M, Deininger MW, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013; 122: 872–884.

  9. Etinne G, Guilhot J, et al: Long–term follow–up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol, 2017; 35: 298–305.

  10. 日本血液学会編：慢性骨髄性白血病/骨髄増殖性腫瘍 (CML/MPN). 造血器腫瘍診療ガイドライン 2018年版補訂版，金原出版，2020; 89–120.

  11. Bonifacio M, Stagno F, et al: Management of chronic myeloid leukemia. Front Oncol, 2019; 25; 1132.

  12. Saussele S, Lauseker M, et al: Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010; 115: 1880–1885.